PROCEPT BioRobotics stock
PRCTNASDAQPROCEPT BioRobotics Corporation, HealthcareISIN US74276L1052
41Score 41 out of 100, Weak
Price and trend
64 / 100
Price history
−24% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 2.5% above it.
Since March 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 70).
The price is 35% below its 52-week high. Largest decline in 5 years: 83% (December 2024 to July 2026).
Chart figures for advanced users
- SMA 50$19.47
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.93
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)70
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.69
- The lowest closing price of the last twelve months.
- Resistance$36.10
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- PROCEPT BioRobotics Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $1.35B, is number 52 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $308.05M (up 37.2% year on year) and a loss of $95.57M.
- For fiscal 2026, analysts expect on average revenue of $395.29M (up 28.3%) and adjusted earnings per share of −$1.67.
Show more
- MEQIRI Score 41 out of 100 (Weak): rank 544 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 109% a year since 2020, Medical (Devices) median 13.8%.Growth 70
- More cash than debtCash $218.37M, financial debt $76.99M.Stability 55
Weaknesses
- DilutionShare count up 58% since 2020.Capital allocation 18
- Loss-makingLoss of $114.86M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$126.12M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 41.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17.5% on the twelve months before. Revenue has grown strongly since 2019, at around 92% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 64%, operating −34%, net −31%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported −$0.46 (expected −$0.39)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$1.670.0%
- Revenue
- $395.29M0.0%
- Earnings per share
- −$1.150.0%
- Revenue
- $476.37M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: +5.2%Procedure guidance was lowered by about 7,000 at the midpoint after growth of 21% came in softer than expected; adjusted EBITDA loss is now expected at $30 million to $35 million.
“We now expect adjusted EBITDA loss to be in the range of $35 million to $30 million, while continuing to expect positive adjusted EBITDA in the fourth quarter of 2026 across both the low and high end of our full year revenue guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $498,315 in total. 4 insiders sold, $143,186 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sharma PoojaSale
6 Nov 2026, Chief Strat/Marketing Officer
- Shares
- 4,710
- Price
- $19.71
- Value
- $92,853
- Nouri AlalehSale
9 Sept 2026, EVP, CLO, CORP. SEC.
- Shares
- 297
- Price
- $20.95
- Value
- $6,223
- Templin Barry LSale
9 Sept 2026, EVP, Chief Technology Officer
- Shares
- 373
- Price
- $20.95
- Value
- $7,815
Show 5 more
- Waters KevinSale
9 Sept 2026, EVP, CFO
- Shares
- 373
- Price
- $20.95
- Value
- $7,815
- Wood Larry LPurchase
7 Aug 2026, President, CEO
- Shares
- 23,900
- Price
- $20.85
- Value
- $498,315
- Nouri AlalehSale
8 Jun 2026, EVP, CLO, CORP. SEC.
- Shares
- 285
- Price
- $28.48
- Value
- $8,117
- Waters KevinSale
8 Jun 2026, EVP, CFO
- Shares
- 357
- Price
- $28.48
- Value
- $10,167
- Templin Barry LSale
8 Jun 2026, EVP, Chief Technology Officer
- Shares
- 358
- Price
- $28.48
- Value
- $10,195
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at PROCEPT BioRobotics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Lumexa Imaging HoldingsLMRI $1.53B47
- CONMEDCNMD $1.51B69
- EL.En.ELN.MI $1.48B75
- NovocureNVCR $1.4B30
- Tandem Diabetes CareTNDM $1.31B45
- Integra LifeSciences HoldingsIART $1.15B50
- Alphatec HoldingsATEC $1.14B34
- SI-BONESIBN $1.13B47
ETFs that hold PROCEPT BioRobotics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Robotics & Artificial Intelligence UCITS ETFXB0T | 0.45% | 0.50% | €135.35M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.04% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.04% | 0.30% | €2.17B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.03% | 0.30% | €185.82M |
| Amundi MSCI Robotics & AI UCITS ETF AccGOAI | 0.03% | 0.40% | €1.14B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 Nov 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.